Sarepta Therapeutics Inc

SRPT

18.500USD

+1.470+8.63%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Sarepta Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

89 / 159

Overall Ranking

236 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Sarepta Therapeutics Inc Highlights

StrengthsRisks

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 103.85% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is -6.85, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 90.74M shares, decreasing 17.69% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 854.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 2.36.

Analyst Rating

Based on 27 analysts

Hold

Current Rating

30.319

Target Price

+78.03%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Sarepta Therapeutics Inc is 7.27, ranking 121 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 399.36M, representing a year-over-year decrease of 14.52%, while its net profit experienced a year-over-year decrease of 635.38%.

Score

Industry at a Glance

Previous score

7.27

Change

0



Financials

5.82

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.69

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.63

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.19

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Sarepta Therapeutics Inc is 7.20, ranking 91 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -6.85, which is -5493.01% below the recent high of 369.56 and -557.34% above the recent low of -45.04.

Score

Industry at a Glance

Previous score

7.20

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 89/159

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Sarepta Therapeutics Inc is 6.37, ranking 130 out of 159 in the Pharmaceuticals industry. The average price target is 17.50, with a high of 185.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

6.37

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Sarepta Therapeutics Inc is 6.58, ranking 118 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 23.16 and the support level at 15.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.25

Change

0.33

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Sarepta Therapeutics Inc is 7.00, ranking 44 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 86.59%, representing a quarter-over-quarter increase of 7.52%. The largest institutional shareholder is The Vanguard, holding a total of 11.73M shares, representing 11.19% of shares outstanding, with 22.13% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

10.79M

+1.37%

BlackRock Institutional Trust Company, N.A.

11.52M

+17.10%

State Street Investment Management (US)

5.30M

+12.99%

Two Sigma Investments, LP

4.10M

-1.24%

Barry (Richard J)

3.21M

+1.02%

Erste Asset Management GmbH

2.69M

+65.65%

Renaissance Technologies LLC

Star Investors

2.65M

+324.38%

abrdn Inc.

1.98M

+59.59%

UBS Financial Services, Inc.

1.98M

+315.87%

D. E. Shaw & Co., L.P.

2.01M

-60.33%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Sarepta Therapeutics Inc is 3.68, ranking 100 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.42. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Sarepta Therapeutics Inc

SRPT

6.56 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

9.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.92 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.86 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Regeneron Pharmaceuticals Inc

REGN

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mirum Pharmaceuticals Inc

MIRM

8.70 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment